MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-07-2025
Computer Programs and Systems Revenue 2011-2025 | CPSI
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Computer Programs and Systems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 339 M | 327 M | 281 M | 264 M | 275 M | 280 M | 277 M | 267 M | 182 M | 205 M | 201 M | 183 M | 173 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 339 M | 173 M | 250 M |
Quarterly Revenue Computer Programs and Systems
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.1 M | 85.7 M | 87.2 M | 84.7 M | 85.6 M | 84.1 M | 82.7 M | 84.6 M | 86.2 M | - | 82.8 M | 82.7 M | 77.9 M | - | 70.1 M | 68.5 M | 68 M | 66.8 M | 68.3 M | 59.5 M | 69.8 M | 70.6 M | 68.7 M | 66.2 M | 66.2 M | 72.3 M | 69.3 M | 67.9 M | 70.9 M | 78.1 M | 67.1 M | 67.7 M | 64.1 M | 64.6 M | 64.7 M | 68.4 M | 69.6 M | 44.2 M | 44.6 M | 47.1 M | 46.2 M | 46.3 M | 53.3 M | 53.1 M | 52.1 M | 51.3 M | 46.8 M | 53.3 M | 49.5 M | 47.9 M | 45.2 M | 45.7 M | 44.5 M | 42.2 M | 42 M | 48.8 M | 40.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 87.2 M | 40.4 M | 64 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Health information services industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Covetrus
CVET
|
4.58 B | - | - | $ 2.94 B |  USA |
 |
Cerner Corporation
CERN
|
5.76 B | - | - | $ 27.9 B | USA |
 |
Accolade
ACCD
|
170 M | - | 0.29 % | $ 206 M | USA |
 |
Castlight Health, Inc.
CSLT
|
147 M | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
673 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
668 M | - | - | $ 6.37 B | USA |
 |
Progyny
PGNY
|
298 M | $ 25.95 | 1.72 % | $ 2.23 B | USA |
 |
Change Healthcare
CHNG
|
3.09 B | - | - | $ 9.03 B | USA |
 |
iCAD
ICAD
|
19.6 M | - | - | $ 102 M | USA |
 |
MTBC
MTBC
|
111 M | - | -0.58 % | $ 51.7 M | USA |
 |
Evolent Health
EVH
|
382 M | $ 4.15 | 0.24 % | $ 389 M | USA |
 |
Health Catalyst
HCAT
|
307 M | $ 2.43 | 2.1 % | $ 146 M | USA |
 |
HealthStream
HSTM
|
292 M | $ 23.69 | -0.59 % | $ 720 M | USA |
 |
Akerna Corp.
KERN
|
20.5 M | - | - | $ 161 M | USA |
 |
OptimizeRx Corporation
OPRX
|
71.5 M | $ 12.53 | -1.8 % | $ 215 M | USA |
 |
HealthEquity
HQY
|
262 M | $ 93.67 | 1.32 % | $ 8.01 B | USA |
 |
American Well Corporation
AMWL
|
254 M | $ 4.59 | 0.44 % | $ 68.8 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
1.5 B | - | -10.39 % | $ 886 M | USA |
 |
Phreesia
PHR
|
356 M | $ 17.12 | 1.63 % | $ 934 M | USA |
 |
Premier
PINC
|
263 M | $ 28.26 | - | $ 2.33 B | USA |
 |
GoodRx Holdings
GDRX
|
792 M | $ 2.76 | -0.36 % | $ 1.06 B | USA |
 |
So-Young International
SY
|
-1.52 M | $ 2.65 | -5.54 % | $ 210 M |  China |
 |
Omnicell
OMCL
|
1.11 B | $ 46.4 | 1.34 % | $ 2.14 B | USA |
 |
1Life Healthcare
ONEM
|
623 M | - | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
1.47 B | - | - | $ 3.81 B | USA |
 |
10x Genomics
TXG
|
619 M | $ 16.61 | -0.51 % | $ 1.95 B | USA |
 |
NantHealth
NH
|
67 M | - | -46.64 % | $ 10.4 M | USA |
 |
Zhongchao
ZCMD
|
16.3 M | $ 0.48 | -9.76 % | $ 2.5 M | China |
 |
NextGen Healthcare
NXGN
|
557 M | - | - | $ 1.6 B | USA |
 |
Schrödinger
SDGR
|
208 M | $ 18.38 | - | $ 1.34 B | USA |
 |
Signify Health
SGFY
|
184 M | - | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
17.9 M | - | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
2.57 B | $ 7.12 | -1.66 % | $ 1.21 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
300 M | - | - | $ 255 M | USA |
 |
Veeva Systems
VEEV
|
2.36 B | $ 224.44 | 0.51 % | $ 36 B | USA |
 |
SCWorx Corp.
WORX
|
2.99 M | $ 0.2 | 0.3 % | $ 292 K | USA |